Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inozyme Pharma ( (INZY) ) has issued an update.
On May 16, 2025, Inozyme Pharma entered into a Merger Agreement with BioMarin Pharmaceutical and Incline Merger Sub. Subsequently, on May 30, 2025, the company’s Board of Directors approved transaction bonuses for key executives, contingent on the merger’s completion, to incentivize continued employment through the closing date.
The most recent analyst rating on (INZY) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Inozyme Pharma stock, see the INZY Stock Forecast page.
Spark’s Take on INZY Stock
According to Spark, TipRanks’ AI Analyst, INZY is a Underperform.
Inozyme Pharma’s stock score reflects its early-stage biotechnology status with significant operational losses, zero revenue, and ongoing cash burn. Technical indicators show short-term momentum but highlight potential overbought conditions. The negative P/E ratio underscores the lack of profitability, and with no earnings data or corporate events provided, the score is primarily driven by weak financial performance.
To see Spark’s full report on INZY stock, click here.
More about Inozyme Pharma
Inozyme Pharma, Inc. operates in the pharmaceutical industry, focusing on developing therapies for rare mineralization disorders.
Average Trading Volume: 2,021,184
Technical Sentiment Signal: Buy
Current Market Cap: $256.3M
For an in-depth examination of INZY stock, go to TipRanks’ Stock Analysis page.